Triple Negative Breast Cancer Trial

Inclusion Criteria: * Histologically confirmed ER-, PR-, primary breast cancer * Histologically confirmed HER2- primary breast cancer * Measurable confirmed metastatic or recurrent locally advanced disease unsuitable for local therapy but suitable for taxane chemotherapy * Patients with stable, treated bain metastases will be eligible providing informed consent can be given and that other sites of measurable disease are present. * Patients with bone metastases currently receiving bisphosphonates for palliation will be eligible providing informed consent can be given and that other sites of measurable disease are present * ECOG Performance Status 0, 1, or 2 * Adequate haematology, biochemical indices (FBC, U \& Es) * LFTs = Normal bilirubin, AST and/or ALT = 3 x ULN if Alk Phos \>5 x ULN (or an isolated elevation AST/ALT of ≤5 x ULN * Adequate renal function - Creatinine clearance of \>25mls per minute * Written informed consent, able to comply with treatment and follow up Exclusion Criteria: * Original primary tumour or subsequent relapse known to be positive for any of ER, PR, or HER2 receptors * Patients unfit for chemotherapy or those with neuropathy \>grade 1 (sensory or motor) * Known allergy to platinum compounds or to mannitol * Known sensitivity to taxanes * Patients with inoperable locally advanced disease suitable for local radiotherapy or an anthracycline containing regimen * Previous chemotherapy for metastatic disease other than an anthracycline as in inclusion criteria above * Previous exposure to a taxane in adjuvant chemotherapy within 12 months of trial entry * Previous treatment with a taxane for recurrent locally advanced disease * Previous treatment with a platinum chemotherapy drug * LFTs = Abnormal bilirubin (\> ULN), AST and/or ALT \>3 X ULN and Alk Phos \>5 x ULN (or an isolated elevation AST/ALT of \>5 x ULN) * Patients with a life expectancy of less than 3 months * Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous call carcinoma of the skin, unless there has been a disease free interval of at least 10 years * Previous or synchronous second breast cancer (unless also confirmed ER-, PR- and HER2-) * Patients with bone limited disease * Other serious uncontrolled medical conditions or concurrent medical illness likely to compromise life expectancy and/or the completion of trial therapy * Pregnant, lactating or potentially childbearing women not using adequate contraception